1.

Urinary tract infection in patients with diabetes

Dr Reuben Johnson

Dr Jayanthi Savio

Dr Jyothi Idiculla

1

Research Society

6 months

Completed

2.

Diabetes and extrapulmonary TB- A cohort study

Dr Akhil Xavier

Dr Nitin Yashas

Dr G D ravindran

Dr Jyothi Idiculla

3 &

1

Applied to Tuberculosis Association of India

6 months

Ongoing

3

Volasertib in treatment of acute myeloid leukemia

Dr. Ratnamala Choudhury

Dr. Cecil Ross

1

Boehinger

3years

completed

4

A study to evaluate predictors of glycemic control among adult patientwith type 2 diabetes mellitus patients attending a tertiary care centre: A cross sectional study

Dr.Soumya Umesh

Dr. Thenmozhi

Dr.Jananee M

Dr. Farahnaaz Fathima

Dr.Belinda

3

Nil

1 year

Ongoing

5

Open label multicentric study of romiplostim in adults with chronic immune thrombocytopenia

Dr. Sanjuktha

Dr. Cecil Ross

1

Lambda therapeutics

1 year

Ongoing

6

Prospective, open-label, uncontrolled, phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in subjects with congenital fibrinogen deficiency.

Dr. Cecil Ross

1

2014-till date

Ongoing

7

Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate Pharmacokinetic, Efficacy, and Safety of a New Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients with Congenital Afibrinogenaemia.

Dr. Cecil Ross

1

2015-till date

Ongoing

8

Phase IV, Open Label, not comparative, naturalistic study, to determine the Efficacy, Safety in Immune Tolerance Induction by Factor VIII concentrate containing Von Willebrand factor, in severe or moderate Haemophilia A patient with inhibitors.

Dr. Cecil Ross

1

2014-till date

Ongoing

9

ASPIRE: An Open-Label Multicenter Evaluation of the Safety, pharmacokinetics, and Efficacy of Recombitant Factor VIII Fc Fusion Protein( rFVIIIFc)in the Prevention and and treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A

Dr. Cecil Ross

1

2012-till date

Ongoing

10

BYOND: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B

Dr. Cecil Ross

1

2012-till date

Ongoing

11

MUSFIH-PRO: Assessment of the effectiveness of prophylactic replacement of lower than ‘standard’ doses of clotting factor concentrates in children with severe haemophilia A.

Dr. Cecil Ross

1

2016-till date

Ongoing

12a

12b

ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Dr. Cecil Ross

1

2017-

Pending IEC clearance

13

Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%).

Dr. Cecil Ross

1

2017-

Pending IEC clearance

14

A Single-Arm, Multicenter Phase IIIB Clinical Trial to evaluate the Safety and tolerability of prophylactic Emicizumab In Hemophilia A Patients with Inhibitors.

Dr. Cecil Ross

1

2017-

Pending IEC clearance

15

Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India.

Dr. Cecil Ross

1

2017-

Pending IEC clearance